<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.85080</article-id><article-id pub-id-type="publisher-id">ACM-26020</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180500000_76167568.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  二甲双胍对血浆维生素B12和同型半胱氨酸影响的研究新进展
  New Research Progress of the Effect of Metformin on Plasma Vitamin B12 and Homocysteine
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>柳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>昆全</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>湖北医药学院附属国药东风总医院内分泌科，湖北 十堰</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>05</issue><fpage>480</fpage><lpage>485</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    二甲双胍因其有效的降糖、减重、降压、调脂、改善纤溶活性及胰岛素抵抗、治疗多囊卵巢综合症及非酒精性脂肪肝等作用，且副作用轻微，被广泛用于治疗2型糖尿病(Type 2 Diabetes Mellitus, T2DM)，目前已成为T2DM治疗的一线用药。近些年国内外部分学者认为，长期服用二甲双胍治疗影响消化道维生素B12 (VitB12)的吸收，从而升高血浆同型半胱氨酸(Homocysteine, Hcy)，进一步促进心血管疾病和糖尿病并发症的发生。建议二甲双胍联合VitB12治疗糖尿病人，可预防血浆同型半胱氨酸升高，延缓糖尿病各种并发症的发生。同时也为临床二甲双胍的应用提供帮助和指导。
    Metformin is effective in reducing glucose, reducing body weight, lowering blood pressure, regu-lating blood lipids, improving fibrinolytic activity and insulin resistance, treating polycystic ovary syndrome and nonalcoholic fatty liver with mild side effects. It has been widely used in the treat-ment of type 2 diabetes mellitus (T2DM) and has become a first-line drug for type 2 diabetes mellitus treatment. In recent years, some scholars at home and abroad believe that long-term use of metformin therapy affects the absorption of vitamin B12 in the digestive tract, thus increasing the plasma homocysteine level and further promoting cardiovascular disease and the occurrence of diabetic complications. It is suggested that metformin combined with vitamin B12 in the treatment of diabetic patients can prevent the increase of plasma homocysteine and delay the occurrence of various complications of diabetes. At the same time, it also provides help and guidance for the clinical application of metformin. 
  
 
</p></abstract><kwd-group><kwd>二甲双胍，维生素B12，同型半胱氨酸, Metformin</kwd><kwd> Vitamin B12</kwd><kwd> Homocysteine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>二甲双胍对血浆维生素B12和同型半胱氨酸 影响的研究新进展<sup> </sup></title><p>陈柳，郭昆全<sup>*</sup></p><p>湖北医药学院附属国药东风总医院内分泌科，湖北 十堰</p><disp-formula id="hanspub.26020-formula76"><graphic xlink:href="//html.hanspub.org/file/7-1570617x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年6月19日；录用日期：2018年7月9日；发布日期：2018年7月23日</p><disp-formula id="hanspub.26020-formula77"><graphic xlink:href="//html.hanspub.org/file/7-1570617x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>二甲双胍因其有效的降糖、减重、降压、调脂、改善纤溶活性及胰岛素抵抗、治疗多囊卵巢综合症及非酒精性脂肪肝等作用，且副作用轻微，被广泛用于治疗2型糖尿病(Type 2 Diabetes Mellitus, T2DM)，目前已成为T2DM治疗的一线用药。近些年国内外部分学者认为，长期服用二甲双胍治疗影响消化道维生素B12 (VitB12)的吸收，从而升高血浆同型半胱氨酸(Homocysteine, Hcy)，进一步促进心血管疾病和糖尿病并发症的发生。建议二甲双胍联合VitB12治疗糖尿病人，可预防血浆同型半胱氨酸升高，延缓糖尿病各种并发症的发生。同时也为临床二甲双胍的应用提供帮助和指导。</p><p>关键词 :二甲双胍，维生素B12，同型半胱氨酸</p><disp-formula id="hanspub.26020-formula78"><graphic xlink:href="//html.hanspub.org/file/7-1570617x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1570617x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-1570617x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>T2DM是由于胰岛素分泌相对不足或胰岛素作用缺陷引起的以慢性高血糖为特征的代谢性疾病。40年来，随着我国人口老龄化与生活方式的变化，糖尿病从少见病变成一个流行病，糖尿病患病率从1980年的0.67%飙升至2013年的10.4% [<xref ref-type="bibr" rid="hanspub.26020-ref1">1</xref>] 。药物治疗是抗高血糖的首选方式，其中二甲双胍是大多数指南推荐的一线药物，也广泛应用于多囊卵巢综合征(Polycystic ovary syndrome, PCOS)、糖尿病前期和其他涉及胰岛素抵抗的疾病 [<xref ref-type="bibr" rid="hanspub.26020-ref2">2</xref>] 。二甲双胍降血糖机制主要通过 [<xref ref-type="bibr" rid="hanspub.26020-ref3">3</xref>] ：1) 作用于肝脏，抑制糖异生，减少肝糖输出；2) 作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；3) 作用于肠道，抑制肠壁细胞摄取葡萄糖，提高GLP-1水平。对T2DM患者，若无二甲双胍使用禁忌或药物耐受，二甲双胍应一直保留在糖尿病的治疗中 [<xref ref-type="bibr" rid="hanspub.26020-ref3">3</xref>] 。但有相关研究认为，长期二甲双胍的治疗可降低血浆VitB12的浓度，升高血浆Hcy水平，进一步促进糖尿病并发症的发生，其不良影响可能会制约二甲双胍的普遍应用。但也有研究认为，二甲双胍可降低血浆Hcy，长期服用可防治心血管事件。本文就二甲双胍对血浆VitB12和Hcy影响的研究新进展作以下综述。</p></sec><sec id="s4"><title>2. 二甲双胍对血浆VitB12的影响</title><p>目前关于二甲双胍与血清VitB12水平相关性的研究结论尚不完全一致。有研究 [<xref ref-type="bibr" rid="hanspub.26020-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.26020-ref5">5</xref>] 认为二甲双胍可引起血清VitB12水平下降，并与二甲双胍治疗时间及剂量明显相关。关于二甲双胍降低血清VitB12水平的机制包括以下几个方面：1) 影响回肠末端钙依赖的维生素B12-内因子(IF)复合物与回肠末端黏膜上皮细胞Cubilin受体的结合过程 [<xref ref-type="bibr" rid="hanspub.26020-ref6">6</xref>] ；2) 二甲双胍相关的胃肠功能紊乱及抑酸剂的使用减少胃酸和IF的分泌，从而影响维生素B12-IF复合物的形成和吸收 [<xref ref-type="bibr" rid="hanspub.26020-ref7">7</xref>] ；3) 二甲双胍竞争性抑制VitB12在回肠末端的吸收，或使介导VitB12吸收的酶失活 [<xref ref-type="bibr" rid="hanspub.26020-ref8">8</xref>] ；4) 二甲双胍通过增加VitB12在肝脏的蓄积而使血清VitB12水平下降 [<xref ref-type="bibr" rid="hanspub.26020-ref9">9</xref>] 。国外学者Out等 [<xref ref-type="bibr" rid="hanspub.26020-ref5">5</xref>] 通过52个月的二甲双胍对安慰剂治疗T2DM的随机对照实验，证实二甲双胍不仅降低了血清VitB12，同时也升高了血清甲基丙烯酸甲酯，从而加重了神经病变评分。Aroda等 [<xref ref-type="bibr" rid="hanspub.26020-ref10">10</xref>] 的糖尿病预防计划研究结果也证实了长期二甲双胍的使用和VitB12的缺乏有关，并且长期的缺乏可使贫血的发生率增加，建议二甲双胍使用者应常规监测VitB12水平。Lohmann等 [<xref ref-type="bibr" rid="hanspub.26020-ref11">11</xref>] 的随机对照实验表明，二甲双胍治疗6个月后维生素B12缺乏症发生率增加，但与贫血无关，认为需要更长的二甲双胍治疗时间进一步证明。Nervo等 [<xref ref-type="bibr" rid="hanspub.26020-ref12">12</xref>] 的横研究断面表明，二甲双胍治疗的糖尿病患者有VitB12缺乏的高发病率，且老年患者，长期二甲双胍治疗的患者以及低VitB12摄取的患者更容易发生VitB12缺乏。</p><p>PCOS是育龄妇女最常见的内分泌紊乱性疾病，其病理生理改变范围广泛，涉及神经内分泌、糖代谢、脂代谢、卵巢调控因素异常。育龄妇女中PCOS的患病率约为5%~10%，临床主要表现为月经失调、肥胖、多毛、不孕等。高雄激素血症、高胰岛素血症和胰岛素抵抗(IR)是其重要的病理生理特征 [<xref ref-type="bibr" rid="hanspub.26020-ref13">13</xref>] 。二甲双胍1500~2500 mg/d，伴或不伴有糖尿病者均可使用，能有效地降低体重，改善胰岛素敏感性，降低胰岛素水平，使毛发减少甚至可恢复月经与排卵。Esmaeilzadeh等 [<xref ref-type="bibr" rid="hanspub.26020-ref14">14</xref>] 的干预性研究表明，6个月的二甲双胍治疗PCOS患者可使血浆VitB12降低，且有统计学意义，尤其对肥胖以及高胰岛素血症的PCOS患者VitB12下降更明显。</p><p>妊娠糖尿病(Gestational diabetes mellitus, GDM)是妊娠前糖代谢正常或有潜在糖耐量减退，妊娠期才出现的糖尿病。GDM患者糖代谢多数于产后能恢复正常，但将来患2型糖尿病机会增加。传统观点认为二甲双胍禁用于GDM，因此临床上通常用胰岛素降糖治疗。但近年有学者发现，孕前和孕早期使用二甲双胍不仅不会增加胎儿畸形，而且对轻度胰岛素抵抗患者还可提高受孕率。Gatford等 [<xref ref-type="bibr" rid="hanspub.26020-ref15">15</xref>] 通过用二甲双胍和胰岛素对比治疗GDM患者，并测定血浆VitB12的水平，发现二甲双胍治疗的GDM患者血浆VitB12下降的更多，同时也认为二甲双胍治疗GDM是安全的，但是并没有说明妊娠期间使用二甲双胍是否需要额外补充VitB12或其它物质。</p><p>但也有部分研究报道，长期二甲双胍的使用并未引起血浆VitB12的缺乏。Greibe等[<xref ref-type="bibr" rid="hanspub.26020-ref9">9</xref>]的动物实验结果显示：二甲双胍仅改变了体内VitB12的组织分布，增加了肝脏蓄积的VitB12，减少了循环中及肾脏的VitB12，并未减少体内总的VitB12的量。同时，也有国外学者 [<xref ref-type="bibr" rid="hanspub.26020-ref16">16</xref>] 的横断面对照研究表明，无论是否有二甲双胍治疗，血浆VitB12的水平没有任区别，认为二甲双胍并没有引起血浆VitB12的缺乏，考虑可能与二甲双胍使用的时间及剂量有关。</p></sec><sec id="s5"><title>3. 二甲双胍对血浆Hcy的影响</title><p>目前二甲双胍与血浆Hcy水平相关性的研究结论也不完全一致。有研究 [<xref ref-type="bibr" rid="hanspub.26020-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.26020-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.26020-ref19">19</xref>] 认为长期服用二甲双胍可使血浆Hcy水平上升。Hcy是含硫氨基酸代谢过程中的重要中间产物，其在体内的代谢途径主要有以下几种：1) 转硫化途径：Hcy在胱硫醚-β-合成酶催化下，与丝胺酸缩合形成胱硫醚，胱硫醚在r-胱硫醚酶催化下进一步裂解为胱氨酸和α-丁酮酸，而维生素B6为这个过程的辅助因子。此途径除合成Hcy外，还能有效降解甲基转移中不需要的过剩Hcy。2) 再甲基化途径：Hcy在蛋氨酸合成酶作用下，以5-甲基四氢叶酸为甲基供体，再甲基化形成蛋氨酸，其中VitB12是这个过程的辅助因子。长期服用二甲双胍会引起血浆VitB12和叶酸水平下降，因此任何影响二者含量的因素都可使得Hcy再甲基化形成蛋氨酸过程受阻，从而引起血浆Hcy升高。</p><p>Mohammadi等 [<xref ref-type="bibr" rid="hanspub.26020-ref17">17</xref>] 研究表明T2DM患者在单独服用二甲双胍后可明显升高血浆Hcy，尤其是在男性糖尿病患者中。然而，如果在使用二甲双胍的同时联合使用叶酸(FA)，可以预防血浆Hcy浓度增加，早期预防或延缓大血管并发症的出现，可能有助于降低心脑血管的患病率和病死率。Vrbikova等 [<xref ref-type="bibr" rid="hanspub.26020-ref18">18</xref>] 认为，短期4周持续的二甲双胍治疗(1000 mg/天)，就可以明显的增加PCOS患者血浆中的Hcy。Kilicdag等 [<xref ref-type="bibr" rid="hanspub.26020-ref19">19</xref>] 也显示PCOS女性在二甲双胍持续治疗3个月后，血浆中的Hcy显著升高，但是治疗前和治疗后相比，胰岛素抵抗指数，体重指数，FA和VitB12的基本水平未见明显变化。有荟萃分析表明 [<xref ref-type="bibr" rid="hanspub.26020-ref20">20</xref>] ，GDM妇女与糖耐量正常的妇女相比，血浆Hcy水平显著升高，而且在妊娠中期Hcy升高的更多。那么当短期二甲双胍治疗GDM患者时，可引起血清VitB12下降，从而导致Hcy再甲基化过程受阻，进一步加重形成高Hcy血症。对妊娠期胎儿的发育造成不良影响，并且可增加妊娠高血压病、羊水过多、早产及剖宫产等疾病发生率。</p><p>但也有研究认为二甲双胍治疗能够引起血浆Hcy下降，从而使患者的心血管获益，对早期T2DM的治疗具有较好的疗效，究其原因，主要是因为二甲双胍能使T2DM患者血液循环中的凝血因子VII抗原下降和纤溶酶原激活剂抑制因子-1 (PAI-1)降低有关，从而降低T2DM患者血栓形成的危险。国内学者付勇南等 [<xref ref-type="bibr" rid="hanspub.26020-ref21">21</xref>] 的细胞实验表明，高Hcy可降低内皮细胞的细胞活力，增加氧化应激，促使内皮细胞受损，而二甲双胍的治疗可能通过激活AMPK通路，抑制血管内皮细胞的氧化应激，使细胞内的超氧阴离子、羟自由基、氧自由基等活性水平下降，抑制Hcy的内皮损伤作用，从而产生血管内皮细胞保护作用，因此可发挥心血管保护作用。Hoogeveen等 [<xref ref-type="bibr" rid="hanspub.26020-ref22">22</xref>] 在早期的研究就表明，持续二甲双胍治疗T2DM患者至少6个月，对血浆总的Hcy影响不大。此外，Carlsen等 [<xref ref-type="bibr" rid="hanspub.26020-ref23">23</xref>] 也报道了二甲双胍治疗PCOS患者虽可使血清FA和VitB12降低，但对患者血浆Hcy水平没有影响。国内也有学者 [<xref ref-type="bibr" rid="hanspub.26020-ref24">24</xref>] 显示二甲双胍治疗PCOS患者时程达3个月则可显著降低患者血清Hcy，继续延长治疗时间并不会进一步降低血清Hcy。此外，肥胖的PCOS女性在二甲双胍治疗后血清Hcy水平下降更明显。其原因可能是二甲双胍可减轻体重，改善胰岛素抵抗和高胰岛素血症。国内有病例对照研究 [<xref ref-type="bibr" rid="hanspub.26020-ref25">25</xref>] 表明，二甲双胍联合胰岛素治疗GDM患者后胱抑素C与Hcy均显著降低，差异有统计学意义(P &lt; 0.05)。且二甲双胍治疗后妊娠高血压病、羊水过多、早产及剖宫产发生率均降低，因此认为二甲双胍联合胰岛素治疗GDM可以较好地控制血糖，降低血清胱抑素C与Hcy，并显著改善母婴结局。</p></sec><sec id="s6"><title>4. 二甲双胍对血浆VitB12和Hcy影响与糖尿病神经血管并发症的关系</title><p>Hcy是心脑血管疾病的独立危险因素，高Hcy血症可能促进糖尿病患者发生血管病变，机制可能有以下几种 [<xref ref-type="bibr" rid="hanspub.26020-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.26020-ref27">27</xref>] ：1) 内皮毒性作用：Hcy可引起血管内皮细胞的损伤，破坏血管壁的弹力层和胶原纤维。2) 刺激血管平滑肌细胞增生：Hcy可直接诱导血管平滑肌细胞增殖，并通过信号传导的方式干扰血管平滑肌细胞的正常功能。3) 致血栓作用：Hcy促进血栓调节因子的表达，激活蛋白C，使凝血因子XII、V和血小板内前列腺素合成增加，从而促进血小板的粘附和聚集。4) 糖类、蛋白质、脂肪代谢紊乱：动脉内皮损伤时，Hcy可促进脂质沉积于细胞壁，刺激泡沫细胞形成，并改变动脉壁糖蛋白分子的纤维化结构，促进斑块钙化，导致粥样硬化。5) 协同糖尿病中的糖基化终末代谢产物加剧血管内皮损伤，从而促使糖尿病患者尿微量清蛋白的发生。</p><p>有学者认为，服用二甲双胍治疗T2DM可致血清VitB12降低，因此较易出现贫血和糖尿病周围神经病变等并发症，同时血浆Hcy升高，进一步加重糖尿病心脑血管并发症及周围神经病变。Roy等 [<xref ref-type="bibr" rid="hanspub.26020-ref28">28</xref>] 的横断面研究证实了这一观点，表明短期二甲双胍的治疗就可以引起血清VitB12的降低和Hcy的升高，这正是T2DM患者患糖尿病周围神经病的原因，建议对于用二甲双胍治疗的糖尿病患者可以早期进行VitB12和叶酸的干预及定期分析，从而降低糖尿病周围神经病变的发生率。Sato等 [<xref ref-type="bibr" rid="hanspub.26020-ref29">29</xref>] 的研究表明，二甲双胍引起糖尿病患者VitB12的降低与Hcy的升高有关，同时，高Hcy血症可致糖尿病视网膜病变。另外，有学者也证实了Hcy、FA、维生素B6及VitB12含量与糖尿病及其并发症密切相关，补充FA及VitB12治疗可能有助于改善预后。</p><p>但是，国内也有研究 [<xref ref-type="bibr" rid="hanspub.26020-ref30">30</xref>] 认为初发的T2DM患者已经存在Hcy升高，颈动脉内膜增厚和神经病变，经过1年的二甲双胍干预治疗后，Hcy和颈动脉内膜中层厚度以及神经病变均显著改善，因此认为T2DM患者经二甲双胍治疗后可使大血管病变获益，将二甲双胍应用于临床糖尿病大血管病变的防治值得推广。国外学者Russo等 [<xref ref-type="bibr" rid="hanspub.26020-ref31">31</xref>] 的研究表明二甲双胍治疗与轻度VitB12降低有关，但不会导致糖尿病周围神经病变。Raizada等 [<xref ref-type="bibr" rid="hanspub.26020-ref32">32</xref>] 也证实了二甲双胍治疗后血清VitB12缺乏的糖尿病患者，并没有更高的贫血或糖尿病周围神经病变发生率。</p></sec><sec id="s7"><title>5. 小结</title><p>综上所述，目前国内外大部分研究认为长期二甲双胍治疗可引起VitB12的吸收障碍，从而引起血浆VitB12浓度降低，升高血浆Hcy，进而导致心脑血管并发症和糖尿病周围神经病变的发生。并且建议在二甲双胍治疗的人群中联合应用VitB12和FA可明显减少VitB12缺乏的发生率，可以显著控制患者体内Hcy的增加，预防各种并发症的发生，具有较高的临床应用价值，同时需要定期监测二甲双胍使用者血浆VitB12和Hcy浓度，为临床二甲双胍的使用提供指导意义。更有国外学者Mazokopakis [<xref ref-type="bibr" rid="hanspub.26020-ref33">33</xref>] 建议长期用二甲双胍治疗的患者每年肌肉注射1000 ug的VitB12，不仅可以提供每年VitB12的需要，还可以避免对维生素B12的年度筛查。本综述在其它研究基础之上进一步综述了二甲双胍对血清VitB12和Hcy影响的相对面，且首次综述了二甲双胍对糖尿病神经血管并发症的保护作用，并通过不同的人群进行阐述，具有新颖性。关于二甲双胍使用时间，VitB12减少的量以及血浆Hcy升高幅度之间的关系仍需要进一步的研究证明。</p></sec><sec id="s8"><title>文章引用</title><p>陈 柳,郭昆全. 二甲双胍对血浆维生素B12和同型半胱氨酸影响的研究新进展New Research Progress of the Effect of Metformin on Plasma Vitamin B12 and Homocysteine[J]. 临床医学进展, 2018, 08(05): 480-485. https://doi.org/10.12677/ACM.2018.85080</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26020-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中华糖尿病杂志, 2018, 10(1): 4-67.</mixed-citation></ref><ref id="hanspub.26020-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered App Roach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38, 140-149. https://doi.org/10.2337/dc14-2441</mixed-citation></ref><ref id="hanspub.26020-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2016年版) [J]. 中国糖尿病杂志, 2016, 24(10): 871-884。</mixed-citation></ref><ref id="hanspub.26020-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">张永红. 2型糖尿病患者服用二甲双胍后维生素B12缺失增加[J]. 山西大同大学学报(自然科学版), 2017, 33(4): 48-50.</mixed-citation></ref><ref id="hanspub.26020-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Out, M., Kooy, A., Lehert, P., et al. (2018) Long-Term Treatment with Metformin in Type 2 Diabetes and Methylmalonic Acid: Post Hoc Analysis of a Randomized Controlled 4.3 Year Trial. Journal of Diabetes and Its Complications, 32, 171-178. https://doi.org/10.1016/j.jdiacomp.2017.11.001</mixed-citation></ref><ref id="hanspub.26020-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kocaciftci, G., Aydoǧan, Ü., Akbulut, H., et al. (2013) The Effects of Metformin and Metformin plus Calcium Treatments on Serum Vitamin B12 Levels. Nobel Medicus, 9, 58-63.</mixed-citation></ref><ref id="hanspub.26020-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Varughese, G.I. and Scarpello, J.H.B. (2007) Metformin and Vitamin B12 Deficiency: The Role of H2 Receptor Antagonists and Proton Pump Inhibitors. Age Ageing, 36, 110-111; Discussion 111. https://doi.org/10.1093/ageing/afl139</mixed-citation></ref><ref id="hanspub.26020-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Singh, A.K., Kumar, K., Karmakar, D., et al. (2013) Association of B12 Deficiency and Clinical Neuropathy with Metformin Use in Type 2 Diabetes Patients. Journal of Postgraduate Medicine, 59, 253-257.  
https://doi.org/10.4103/0022-3859.123143</mixed-citation></ref><ref id="hanspub.26020-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Greibe, E., Miller, J.W., Foutouhi, S.H., et al. (2013) Metformin Increases Liver Accumulation of Vitamin B12—An Experimental Study in Rats. Biochimie, 95, 1062-1065. https://doi.org/10.1016/j.biochi.2013.02.002</mixed-citation></ref><ref id="hanspub.26020-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Aroda, V.R., Edelstein, S.L., Goldberg, R.B., et al. (2016) Long-Term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology &amp; Metabolism, 101, 1754-1761. https://doi.org/10.1210/jc.2015-3754</mixed-citation></ref><ref id="hanspub.26020-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lohmann, A.E., Liebman, M.F., Brien, W., et al. (2017) Effects of Metformin versus Placebo on Vitamin B12 Metabo3lism in Non-Diabetic Breast Cancer Patients in CCTG MA.32. Breast Cancer Research and Treatment, 164, 371-378. https://doi.org/10.1007/s10549-017-4265-x</mixed-citation></ref><ref id="hanspub.26020-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Nervo, M., Lubini, A., Raimundo, F.V., et al. (2011) Vitamin B12 in Metformin-Treated Diabetic Patients: A Cross-Sectional Study in Brazil. Revista da Associação Médica Brasileira, 57, 46-49.  
https://doi.org/10.1016/S0104-4230(11)70015-X</mixed-citation></ref><ref id="hanspub.26020-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">郁明霞. 多囊卵巢综合征和心血管并发症[J]. 中国医药指南, 2011, 9(23): 37-39.</mixed-citation></ref><ref id="hanspub.26020-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Esmaeilzadeh, S., Gholinezhad-Chari, M. and Ghadimi, R. (2017) The Effect of Met-formin Treatment on the Serum Levels of Homocysteine, Folic Acid, and Vitamin B12 in Patients with Polycystic Ovary Syndrome. Journal of Human Reproductive Sciences, 10, 95-101. https://doi.org/10.4103/jhrs.JHRS_74_16</mixed-citation></ref><ref id="hanspub.26020-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Gatford, K.L., Houda, C.M., Lu, Z.X., et al. (2013) Vitamin B12 and Homocysteine Status during Pregnancy in the Metformin in Gestational Diabetes Trial: Responses to Maternal Metformin Compared with Insulin Treatment. Diabetes, Obesity and Metabolism, 15, 660-667. https://doi.org/10.1111/dom.12080</mixed-citation></ref><ref id="hanspub.26020-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Rodríguezgutiérrez, R., Montesvillarreal, J., Rodríguezvelver, K.V., et al. (2017) Metformin Use and Vitamin B12 Deficiency: Untangling the Association. The American Journal of the Medical Sciences, 354, 165-171.  
https://doi.org/10.1016/j.amjms.2017.04.010</mixed-citation></ref><ref id="hanspub.26020-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mohammadi, M., Amini, M., Aminiorroay, A., et al. (2009) Effect of Metformin and Folic Acid on Plasma Homocysteine Level in Type 2 Diabetic Patients. International Journal of Medicine &amp; Medical Sciences, 1, 88-90.</mixed-citation></ref><ref id="hanspub.26020-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Vrbíková, J., Bicíková, M., Tallová, J., et al. (2002) Homocysteine and Steroids Levels in Metformin Treated Women with Polycystic Ovary Syndrome. Experimental and Clinical Endo-crinology &amp; Diabetes, 110, 74-76.  
https://doi.org/10.1055/s-2002-23489</mixed-citation></ref><ref id="hanspub.26020-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kilicdag, E.B., Bagis, T., Arim, E., et al. (2005) Administration of B-Group Vitamins Reduces Circulating Homocysteine in Polycystic Ovarian Syndrome Patients Treated with Metformin: A Randomized Trial. Human Reproduction, 20, 1521-1528. https://doi.org/10.1093/humrep/deh825</mixed-citation></ref><ref id="hanspub.26020-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gong, T., Wang, J., Yang, M., et al. (2016) Serum Homocysteine Level and Gestational Diabetes Mellitus: A Meta-Analysis. Journal of Diabetes Investigation, 7, 622-628.</mixed-citation></ref><ref id="hanspub.26020-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">付勇南, 胡金兴, 杨媛, 等. 二甲双胍通过激活AMPK降低同型半胱氨酸对内皮细胞的损伤[J]. 中国动脉硬化杂志, 2016, 24(11): 1081-1085.</mixed-citation></ref><ref id="hanspub.26020-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hoogeveen, E.K., Kostense, P.J., Jakobs, C., et al. (1997) Does Metformin Increase the Serum Total Homocysteine Level in Non-Insulin-Dependent Diabetes Mellitus? Journal of Internal Medicine, 242, 389-394.  
https://doi.org/10.1046/j.1365-2796.1997.00231.x</mixed-citation></ref><ref id="hanspub.26020-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Carlsen, S.M., Kjøtrød, S., Vanky, E., et al. (2007) Ho-mocysteine Levels Are Unaffected by Metformin Treatment in Both Nonpregnant and Pregnant Women with Polycystic Ovary Syndrome. Acta Obstetricia et Gynecologica Scandinavica, 86, 145-150. https://doi.org/10.1080/00016340600855946</mixed-citation></ref><ref id="hanspub.26020-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">孔雯, 肖西悦, 曾天舒, 等. 二甲双胍对多囊卵巢综合征患者血清同型半胱氨酸水平影响的系统评价[J]. 华中科技大学学报(医学版), 2015, 44(5): 540-544.</mixed-citation></ref><ref id="hanspub.26020-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">唐国珍, 张小霞, 谭爱香, 等. 盐酸二甲双胍与门冬胰岛素联合治疗对妊娠期糖尿病孕妇血清胱抑素C、同型半胱氨酸及母婴结局的影响[J]. 中国现代医学杂志, 2016, 26(2): 76-79.</mixed-citation></ref><ref id="hanspub.26020-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Moghadasian, M.H., McManus, B.M. and Frohlich, J.J. (1997) Homocysteine and Coronary Artery Disease, Clinical Evidence and Genetic and Metabolic Back-ground. Archives of Internal Medicine, 157, 2299-2308.  
https://doi.org/10.1001/archinte.1997.00440410025003</mixed-citation></ref><ref id="hanspub.26020-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Matthias, D., Becker, C.H., Riezler, R., et al. (1996) Homocysteine Induced Arteriosclerosis-Like Alterations of the Aorta in Normotensive and Hypertensive Rats Following Application of High Doses of Methionine. Atherosclerosis, 122, 201-216. https://doi.org/10.1016/0021-9150(95)05740-4</mixed-citation></ref><ref id="hanspub.26020-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Roy, R.P., Ghosh, K., Ghosh, M., et al. (2016) Study of Vitamin B12 Deficiency and Peripheral Neuropathy in Metformin-Treated Early Type 2 Diabetes Mellitus. Indian Journal of Endocrinology and Metabolism, 20, 631-637.  
https://doi.org/10.4103/2230-8210.190542</mixed-citation></ref><ref id="hanspub.26020-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Sato, Y., Ouchi, K., Funase, Y., et al. (2013) Relationship be-tween Metformin Use, Vitamin B12 Deficiency, Hyperhomocysteinemia and Vascular Complications in Patients with Type 2 Diabetes. Endocrine Journal, 60, 1275-1280.  
https://doi.org/10.1507/endocrj.EJ13-0332</mixed-citation></ref><ref id="hanspub.26020-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">叶强. 2型糖尿病大血管病变患者二甲双胍治疗后同型半胱氨酸及颈动脉内膜中层厚度的变化关系研究[J]. 中国医学工程, 2014, 22(10): 21.</mixed-citation></ref><ref id="hanspub.26020-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Russo, G.T., Giandalia, A., Romeo, E.L., et al. (2016) Diabetic Neuropathy Is Not Associated with Homocysteine, Folate, Vitamin B12 Levels, and MTHFR C677T Mutation in Type 2 Diabetic Outpatients Taking Metformin. Journal of Endocrinological Investigation, 39, 305-314. https://doi.org/10.1007/s40618-015-0365-9</mixed-citation></ref><ref id="hanspub.26020-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Raizada, N., Jyotsna, V.P., Sreenivas, V., et al. (2017) Serum Vitamin B12 Levels in Type 2 Diabetes Patients on Metformin Compared to Those Never on Metformin: A Cross-Sectional Study. Indian Journal of Endocrinology and Metabolism, 21, 424-428. https://doi.org/10.4103/ijem.IJEM_529_16</mixed-citation></ref><ref id="hanspub.26020-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Mazokopakis, E.E. and Starakis, I.K. (2012) Recommendations for Diagnosis and Management of Metformin-Induced Vitamin B12 (Cbl) Deficiency. Diabetes Research and Clinical Practice, 97, 359-367.  
https://doi.org/10.1016/j.diabres.2012.06.001</mixed-citation></ref></ref-list></back></article>